WHO ICTRP trial
The effect of finasteride and hydroxy chloroquine on frontal fibrosing alopecia
IRCT20210513051276N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20210513051276N1 |
|---|---|
| Public title | The effect of finasteride and hydroxy chloroquine on frontal fibrosing alopecia |
| Scientific title | Clinical trial of Comparison of the efficacy and safety of finasteride and hydroxy chloroquine on frontal fibrosing severity index in patients with frontal fibrosing alopecia |
| Primary sponsor | Esfahan University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Frontal fibrosing alopecia. Cicatricial alopecia, unspecified;L66.9 |
| Interventions | Intervention 1: A group of 15 patients are treated with finasteride tablets of 2.5 mg daily for 6 months. Intervention 2: Intervention group: A group of 15 patients treated with hydroxychloroquine 400 mg daily for 6 months. |
| Registration date | Jun 3, 2021 |
| Target size | 30 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: